LIFECORE BIOMEDICAL, INC. Long-term Line of Credit
LIFECORE BIOMEDICAL, INC. (LFCR) had Long-term Line of Credit of $16.00 million as of 2023-02-26, per its 10-Q filed 2023-06-02.
Discontinued › Balance Sheet › Liabilities
us-gaap:LineOfCredit · last filed 2023-06-02
- 2023-02-26: Long-term Line of Credit $16.00M.
- 2022-05-29: Long-term Line of Credit $0.00.
| Period end | Long-term Line of Credit |
|---|---|
| 2023-02-26 | $16.00M 10-Q · filed 2023-06-02 |
| 2022-05-29 | $0.00 10-Q · filed 2023-06-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |